Revolutionizing dentistry

For the millions of people who stay away from the dentist because they fear the needle and the pain, relief is soon on the way. St. Renatus, LLC plans to introduce the world’s first dental anesthetic administered through the nasal cavity and suitable for use in procedures involving most of the upper teeth.

Product Development

2000: Development of drug/patent application filed
2002: Patent approved
2005: FDA Pre-IND meeting
July 2006: Improved drug formulation completed
Feb. 2007: Phase 1 safety trial completed
January 2009: Phase 2 efficacy trial completed
Sept.2009: St. Renatus hires CEO, Steve Merrick
First Quarter 2011: Estimated start date of Phase 3 FDA clinical studies
Second Half 2011: New Drug Application

Announcements
St. Renatus’ nasal mist technology highlighted in Barcelona, Spain at IADR! Dr. Fadi Ayoub, Assistant Professor in Restorative Dentistry at the University of Buffalo, presented a research poster on St. Renatus’ nasal mist technology at the IADR (International Association for Dental Research) General Session and Exhibition July 14-17 in Barcelona, Spain. Click here for more information and photos from the event.		DPT Laboratories, Ltd completed a batch of our nasal mist drug product on June 30, 2010, to be used for the pharmacokinetics (PK) study and for a final toxicology study.